HOXB13 and neoplasm: HOXB13 can confer tamoxifen resistance by directly downregulating the transcription of estrogen receptor α (ERα), and transcriptionally up-regulated interleukin (IL)-6, activating the mTOR pathway via STAT3 phosphorylation to promote the proliferation of BRCA tumor cells and the recruitment of fibroblast, leading to disease progression and recurrence [23].